Cancer Drug Cull By NHS Sparks Demands For NICE Reform
Disappointed by NHS England’s decision to remove a number of high-cost drugs from the Cancer Drugs Fund, the U.K. pharma industry is focusing its firepower on reforming NICE appraisals.
Disappointed by NHS England’s decision to remove a number of high-cost drugs from the Cancer Drugs Fund, the U.K. pharma industry is focusing its firepower on reforming NICE appraisals.